Program
Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection
Also written as “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection”, “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w” and “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w”.
Its studies are mostly in Multi-centric Castleman's Disease · Arthritis, Rheumatoid, led by Beijing VDJBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing VDJBio | 33 open or running | phase 3since Dec 5, 2024 | Apr 19, 2022 | Jun 9, 2027phase 3 · NCT07872423 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 19, 2022First study: phase 2 study in Idiopathic Multicentric Castleman's DiseaseFirst studyNCT05345522 · 25 enrolled · China
- Dec 5, 2024Phase 3 study in Arthritis, RheumatoidNCT06726096 · 615 planned · China
- Mar 19, 2026Phase 3 study in Multi-centric Castleman's DiseaseNCT07872423 · 45 planned · China
Ahead
- Jun 9, 2027Primary completion: phase 3 study in Multi-centric Castleman's DiseaseNCT07872423
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07872423Multi-centric Castleman's Disease · China | 3 | Recruiting | Jun 9, 2027 | 45 |
| NCT06726096Arthritis, Rheumatoid · China | 3 | By invitation | Apr 20, 2026 | 615 |
| NCT05345522Idiopathic Multicentric Castleman's Disease · China | 2 | Active, not recruiting | Nov 27, 2022 | 25 |
How it is read
Names in the registry
- “Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection”, 1 entry
- “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection”, 1 entry
- “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w”, 1 entry
- “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w”, 1 entry
- “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w”, 1 entry
Conditions, from the studies’ own filings
- Multi-centric Castleman's Disease, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.